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Abstract
Hemoglobin based oxygen carriers (HBOCs) hold promise as an effective emergency
treatment of severe traumatic brain injuries (TBI). In the latest generation of HBOCs,
polynitroxyl-pegylated hemoglobin (PNPH), cell-free hemoglobin is modified with
TEMPO and PEG which reduce the toxicities associated with earlier generations of
HBOCs. In our efforts to optimize the economic and therapeutic impacts of PNPH’s we
have synthesized polydimethylaminoethyl methacrylate (poly-DMAEMA) under
controlled living conditions via reverse addition-fragmentation chain transfer (RAFT)
polymerization. The poly-DMAEMA was then successfully functionalized via
quaternization of its NMe2 groups using chloroacetate derivatives of the TEMPO and
PEG. This process was quantitative and the ratio of the functional groups could be
controlled. In order to bond the functionalized poly-DMAEMA to the hemoglobin
protein, we have explored the synthesis of maleic acid based derivatives. These binding
groups contain a maleic acid and benzyl bromide functionalities to link the cysteine
mercaptan groups of the hemoglobin shell to the NMe 2 groups of the functionalized polyDMAEMA, respectively.
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INTRODUCTION
Traumatic Brain Injury
Traumatic brain injuries (TBI) represent a leading cause of morbidity and mortality in the
United States, affecting 1.7 million Americans annually. Of those cases, 275,000 result in
hospitalization and 52,000 result in mortality. Of those surviving TBI, more than 80,000
cases annually result in a permanent TBI-related disability.1 Furthermore, the World Health
Organization (WHO) predicts TBI will become the leading cause of morbidity and
mortality globally by the year 2020. 2 The detrimental rate of morbidity and mortality in
TBI patients arises largely from secondary complications, namely cerebral ischaemia and
inflammation, as a result of hemorrhaging and cortical impact associated with the injury.
In TBI patients, cerebral ischaemia caused by low cerebral blood flow (CBF) leads to
inadequate oxygenation (hypoxia) and impaired metabolic function in the brain tissue,
producing long term neuropsychological impairment. 3 Along with ischaemia, TBI further
induces an inflammatory response as a result of the release of cellular mediators such as
proinflammatory cytokines, prostaglandins, and free radicals upon initial injury, causing
further neuronal damage.4 Current TBI research therefore aims to develop treatments that
restore normal cerebral blood flow to reduce the degree of secondary injury resulting from
the initial trauma.

Hemoglobin-Based Oxygen Carriers
Hemoglobin-based oxygen carriers (HBOCs) have demonstrated promise as a TBI
treatment by exploiting the oxygen transport mechanism of extracellular hemoglobin (Hb)
to deliver oxygen to injured brain tissue. Hemoglobin is the active tetrameric protein
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component of the red blood cell (RBC), containing iron-porphyrin rings that bind
molecular oxygen in the lungs to deliver to tissues throughout the body (Figure 1).

Figure 1. Crystal structure of the tetrameric protein, hemoglobin. Prosthetic porphyrin rings residing in
each subunit are pictured in green.5

By utilizing the Hb units from lysed RBCs, HBOCs harness the oxygenation capabilities
of the hemoglobin without the complications associated with traditional packed red blood
cell (PRBC) transfusions typically administered

to TBI patients. Namely, PRBC

transfusions rely on viable blood donations and donor-recipient immunocompatibility due
to the antigens coating the RBC membrane, hindering both the availability and use of the
treatment.5 HBOCs, however, utilize hemoglobin purified from readily available human
and bovine blood sources, producing abundant and universally immunocompatible oxygen
carrying units.6 Furthermore, Hb units are comparably one-seventieth the size of an RBC,
allowing for the units to effectively infiltrate and oxygenate swollen tissue that RBCs fail
to reach.5
Despite the inherent advantages of extracellular Hb, first generation HBOCs shed light on
the biophysiological complications that arise from a lack of the regulatory control
mechanisms intrinsic to the RBC. Explicitly, when the tetrameric cell-free Hb units
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naturally present in RBCs at a 5mM concentration are released into the blood at μM
concentrations during HBOC treatments, the Hb units begin to rapidly dissociate into
dimeric subunits that are unregulated in the body, causing unwanted peripheral damage.
The decreased molecular weight of dimeric Hb units causes the units to undergo
unnecessary glomerular filtration, resulting in nephrotoxicity. These dimeric units also
exhibit stronger oxygen affinity and noncooperation with allosteric factors that initiate
oxygen release in the tissue, causing an increase in oxygen binding coupled with a decrease
in peripheral oxygen delivery. Further, the ferrous iron atoms of cell-free Hb dimers have
been shown to be oxidized more readily than those of their tetrameric counterpart,
inhibiting the ability of the porphyrin prosthetic group to bind oxygen. The ferric state of
the dimer moreover induces a cascade of reactive oxygen species (ROC) generating
reactions that cause oxidative stress in the body. Lastly, dimers have been shown to
extravasate and scavenge nitric oxide (NO) produced by the endothelium, inhibiting proper
vasoregulation. By reducing NO availability in the bloodstream, cell-free Hb causes
vasoconstriction that further impedes proper tissue perfusion and oxygenation. 5

Polynitroxyl-Pegylated Hemoglobin
The adverse effects of first generation HBOCs prompted the development of a wide range
of modified HBOCs that seek to reduce the nephrotoxicity, oxidative stress, and NO
scavenging properties of cell-free Hb by artificially preventing the breakdown of the
tetrameric protein into its dimeric form. One such type of modified HBOC is polynitroxy lpegylated hemoglobin (PNPH), a bovine-based Hb unit grafted with polyethylene glycol
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(PEG) and (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl (TEMPO) functionalities to prevent
dimer formation and subsequent toxicity and vasoconstriction (Scheme 1).

Scheme 1. PNPH molecule synthesized via the conjugation of PEG and TEMPO moieties to amino acids
on the shell of cell-free Hb.

In PNPH molecules, PEG, a widely used polymer in biomedical applications, effective ly
increases the size and stability of the Hb unit in a process called PEGylation. Through
PEGylation, the chemically inert polymers are conjugated to amino groups of the primary
protein structure, thus increasing the molecular weight of the protein and subsequently
decreasing glomerular filtration and nitric oxide scavenging while preserving the
functional integrity of the protein. 7 Additionally, the TEMPO moiety, a stable nitroxide
radical, possesses redox metabolic capabilities that mimic the antioxidative control
mechanisms of RBC enzymes to effectively neutralize ROS produced by cell-free Hb,
reducing oxidative stress.8 Studies of PNPH employed for the treatment of TBI have
validated the efficacy of these modifications. In vitro studies that administered PNPH
treatment revealed reduced intracranial pressure, improved cerebral perfusion, and
attenuated edema as compared to traditional PRBC transfusions for TBI treatment.
Furthermore, PNPH requires one sixth of the resuscitation volume of a PRBC transfus io n
to achieve the same effects, due largely in part to the hypercolloidal properties of the polar
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PEG moieties. Decreased resuscitation volume is particularly advantageous in the context
of TBI treatment as high resuscitation volumes further aggravate cerebral edema,
preventing oxygenation.9 The success of in vitro studies has led to the FDA approval of
various PNPH treatments for clinical testing.
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PURPOSE
Although PNPH holds great promise as an effective blood substitute, a cost-effective and
practical synthesis of PNPH for pharmaceutical manufacturing has yet to be developed.
Our research aims to develop a novel and cost-effective synthesis of a PNPH molecule for
pharmaceutical application

via the creation of multifunctional polyacrylates

with

neuroprotective properties for the functionalization of cell-free Hb.
Current synthetic strategies for PNPH molecules involve the conjugation of PEG and
TEMPO moieties to the amino acid residues of the Hb unit via synthetic Hb binding groups.
Initial synthetic approaches lacked amino acid site-selective control of conjugatio n,
increasing moiety dispersity and interfering with the vasoregulatory, antioxidative, and
colloidal properties of the functional Hb molecules. In revised approaches, development of
binding groups with high site specificity permitted control of the patterns of conjugatio n
and subsequent functionality of the molecule. Synthesizing these site-specific binding
groups for both PEG and TEMPO moieties currently requires numerous steps in a costly
procedure in order to yield the final PNPH molecule, limiting widespread pharmaceutica l
application.7
Our proposed synthetic strategy reduces the length and overall cost of PNPH synthesis for
optimal pharmaceutical application by modifying cell-free Hb with functionalized
polyacrylates. In this novel synthesis, acrylate polymers, widely known as acrylics, are
functionalized with PEG and TEMPO moieties as well as site-specific hemoglobin binding
groups for the creation of a multifunctional polyacrylate that can be attached to the cysteine
mercapto groups of the outer hemoglobin shell. The polyacrylate can be functionalized
with all three moieties in varying ratios in a single step process. The functionalized
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polyacrylate can then be subsequently grafted onto the Hb unit, resulting in a novel PNPH
molecule with neuroprotective properties (Scheme 2).

Scheme 2. Modification of cell-free Hb through the conjugation of polyacrylates functionalized with PEG
and TEMPO moieties via a Hb binding group.
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SYNTHETIC APPROACH
Synthesis of Well-Defined Polyacrylates via RAFT
Homogeneity of PNPH molecules is crucial for pharmaceutical application due to strict
quality regulations set forth by the Federal Drug Administration (FDA). For this reason,
the synthesis of polyacrylates with controlled molecular weight and low polydispersity is
imperative to our design of the multifunctional polyacrylate. Reversible AdditionFragmentation Chain Transfer (RAFT) polymerization specifically allows for the control
of molecular weight and polydispersity via the use of a Chain Transfer Agent (CTA) that
mediates the living polymerization. For this novel synthesis, we polymerize the methyl
methacrylate monomer 2-(Dimethylamino)ethyl methacrylate (DMAEMA) via RAFT to
yield a well-defined polymethyl methacrylate (poly-DMAEMA) for functionaliza tio n
(Scheme 3). In order to facilitate RAFT, a CTA containing a phenol group adjacent to a
thiocarbonylthio (S=C–S) bond was synthesized to provide stabilization of the adduct
radical during polymerization propagation. RAFT polymerization of DMAEMA using the
CTA and azobisisobutyronitrile (AIBN) radical initiator yields a poly-DMAEMA with low
polydispersity and controlled molecular weight that can be confirmed via gel permeation
chromatography (GPC). These well-defined polymers can then be functionalized with
TEMPO,

PEG,

and

binding

functionalization reaction.

group

moieties

in

a single

post-polymeriza tio n
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Scheme 3. Polymerization of DMAEMA via RAFT to yield a polyacrylate for post -polymerization
functionalization with TEMP, PEG, and binding group moieties.

Post-Polymerization Functionalization of Polyacrylates
To further reduce the cost and length of the PNPH synthesis, our novel synthetic strategy
seeks to functionalize the polymer is in a single post-polymerization reaction. In this postpolymerization reaction, TEMPO and PEG chloroacetate derivatives as well as synthetic
hemoglobin binding group moieties quaternize the nitrogens of the DMAEMA nitrogen
dimethyl (NMe2 ) groups to create a functionalized polyacrylate (Scheme 3). This synthetic
strategy permits for control of the ratio of TEMPO and PEG functionalities to achieve an
optimal density that reduces the oxidative stress and subsequent toxicity associated with
cell-free Hb. The poly-DMAEMA can be functionalized with 50 – 80% loading density of
TEMPO and PEG to target an average of 10 – 300 moieties per polymer. Each hemoglob in
molecule, containing ten cysteine binding sites on its shell for the binding group moiety,
will hence be able to bind up to 100 – 3000 TEMPO and PEG functionalities per unit, in
addition to those of crosslinked polymers. Confirmation of the attachment of the moieties
to the polymer in the desired ratio can be confirmed via 1 H NMR.

Synthesis of a Binding Group for Attachment to Hemoglobin
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This novel synthesis further reduces the complexity of current PNPH synthetic strategy by
utilizing a maleic anhydride derived hemoglobin binding group to conjugate the
functionalized polymers to the cell-free Hb (Scheme 4). An activated alkyl halide of the
binding group quaternizes the nitrogen of the DMAEMA to attach the moiety to the
polymer. The functionalized binding group then exploits the alkene of the maleic acid in
order to undergo conjugate addition to the cysteine residues of the hemoglobin shell. It is
imperative therefore that the synthesis of the binding group must yield a molecule that
possesses the ability to bind to both the cysteine residues of the hemoglobin as well as the
NMe2 groups of the polymer. The ability of the binding group to attach to the polymer can
also be confirmed via 1 H NMR. The conjugation of the functionalized polymer to the
cysteine residues via the binding group can be confirmed via EPR.

Scheme 4. Conjugate addition of the maleic acid of the binding group to the thiol of the cysteine residue of
the Hb shell. Spacer represents an alkyl halide that can quaternize the NMe 2 groups of the polyacrylate to
functionalize the polymer.
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RESULTS AND DISCUSSION
Post-Polymerization Functionalization with TEMPO and PEG
The poly-DMAEMA has been successfully functionalized with TEMPO and PEG
chloroacetate derivatives in a targeted 60% overall loading based on the number of NMe2
groups available for quaternization, as confirmed by 1 H NMR. In order to yield a
functionalized copolymer, TEMPO and PEG were both treated with chloroacetyl chloride
to yield TEMPO chloroacetate and PEG chloroacetate, which were then reacted with the
poly-DMAEMA by reflux for 24 h at 95 °C. Following treatment with ascorbic acid in
order to visualize the TEMPO moieties, the quaternization of the NMe 2 groups by both
functionalities was confirmed via

1H

NMR (Figure 2). This process was successfully

repeated using varying ratios of TEMPO and PEG [1:1, 5:1, 1:5] respectively,
demonstrating the ability to control the functional density of the polyacrylates. After the
binding group is successfully synthesized and isolated, it can be included in this postpolymerization reaction with the same degree of control.

Scheme 5. Controlled functionalization of the polyacrylate with TEMPO and PEG chloroacetate
derivatives in an overall targeted 60% loading ratio based upon the number of NMe 2 available for
quaternization.
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Figure 2. Synthesis of TEMPO and PEG functionalized copolymers in varying ratios confirmed via 1 H
NMR.

Binding Group Synthesis
In an initial approach to the synthesis of the binding group, bromoethanol was reacted with
maleic anhydride in the presence of triethylamine at room temperature with subsequent
acid addition to yield a pure bromoethylmaleate product 1 (Scheme 6). Using 1 H NMR, the
presence of the isolated product 1 containing both the maleate and activated alkyl bromide
for binding to hemoglobin shell and poly-DMAEMA respectively was confirmed (Figure
3); hydrogen atom a at 6.44 ppm, hydrogen b at 6.47 ppm, hydrogens c at 4.58 ppm, and
hydrogens d at 3.57 ppm. However, the attachment of the synthesized binding group 1 to
the NMe2 groups of the polymer via the alkyl bromide required a temperature of 120 °C
(Scheme

7). Under

such

harsh

conditions,

significant

decomposition

of the

bromoethylmaleate binding group polymer 2 was observed, rendering the binding group
ineffective for this purpose.

Scheme 6. Synthesis of bromoethylmaleate binding group from maleic anhydride and 2-bromoethanol.
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Figure 3. 1 H NMR confirmation of bromoethylmaleate binding group.

Scheme 7. Quaternization of NMe 2 groups of the controlled poly-DMAEMA with the bromoethylmaleate
binding group.

To prevent polymer decomposition during functionalization,

a new approach was

developed in which the alkyl bromide was replaced with a more reactive benzylic bromide
that can facilitate the reaction between the binding group and polymer at lower
temperatures. In this synthetic approach, 2,6-di-tert-butyl-4-methylphenol was first reacted
with N-bromosuccinimide (NBS) via radical substitution initiated by azobisisobutyronitr ile
(AIBN) in acetonitrile under reflux for 3 h to yield the desired intermediate product 3
containing a benzyl bromide with increased reactivity (Scheme 8). The brominated 2,6-ditert-butyl-4-methylphenol 3 precipitated cleanly from the reaction solution and was
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subsequently filtered to isolate the pure desired intermediate as confirmed by 1 H NMR
(Figure 4); hydrogen atoms a at 4.53 ppm, hydrogens b at 7.22 ppm, hydrogens c at 1.46
ppm, and hydrogen d at 5.32 ppm in expected ratios.

Scheme 8. Synthesis of brominated 2,6-di-tert-butyl-4-methylphenol.

Figure 4. 1 H NMR confirmation of the isolated brominated 2,6-di-tert-butyl-4-methylphenol.

Difficulties

arose, however, in functionalizing

the brominated

2,6-di-tert-butyl- 4-

methylphenol 3 with maleic anhydride in order to yield the overall desired binding group
4 with both the benzylic bromide and maleate functionalities. An attempt to react the
hydroxyl group of intermediate 3 with maleic anhydride to create the desired maleate was
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made by stirring compound 3 at room temperature with maleic anhydride in the presence
of triethylamine (Scheme 9); however, no reaction was observed.

Scheme 9. Functionalization of brominated 2,6-di-tert-butyl-4-methylphenol using maleic anhydride.

The approach was subsequently revised to create a more nucleophilic phenolate that
could be reacted with the maleic anhydride to create a maleate intermediate 5 which
could then be functionalized using NBS to yield the desired binding group 4 (Scheme
10). Therefore, 2,6-di-tert-butyl-4-methylphenol was reacted with sodium methoxide to
quantitatively yield the 2,6-di-tert-butyl-4-methylphenolate, which was then reacted with
maleic anhydride at room temperature. Despite the deprotonation of the phenol to
promote the nucleophilic attack of the maleic anhydride, no reaction was observed.

Scheme 10. Functionalization of 2,6-di-tert-butyl-4-methylphenolate using maleic anhydride.
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Due to the difficulties encountered while attempting to functionalize the phenol using
maleic anhydride, a new synthetic approach was designed in which the phenol was replaced
with an aniline possessing a primary amine that could be reacted with the maleic anhydride
to yield a maleimide derivative (Scheme 11). Combining 4-methylaniline and maleic
anhydride at room temperature, the amino group was successfully functionalized to yield
the pure desired maleimide product 6, as confirmed by 1 H NMR (Figure 5).

Scheme 11. Functionalization of 4-methylaniline using maleic anhydride.

Figure 5. 1 H NMR confirmation of the isolated pure maleimide derivative.

In the proceeding reaction, the installment of a benzylic bromide was attempted via a
radical bromination reaction. The maleimide derivative 6 was reacted with NBS in the
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presence of AIBN in a pressure vessel at 110 °C in order to dissolve all the starting
materials (Scheme 12). However, the desired brominated binding group 7 was not
observed via 1 H NMR.

Scheme 12. Radical bromination of the amide derivative using NBS and AIBN.

In an alternative attempt to brominate the benzylic position of the aniline, the approach
was modified slightly by using 4-methylanilinium chloride in place of 4-methylaniline.
The 4-methylanilinium chloride was reacted with NBS in the presence of AIBN in a
pressure vessel at 110°C (Scheme 12). However, the desired brominated anilinium 8 was
still not observed via 1 H NMR.

Scheme 12. Radical bromination of the anilinium using NBS and AIBN.

In the latest revised approach, the phenol derived binding group will be revisited. In place
of 2,6-di-tert-butyl-4-methylphenol, p-cresol will be used, effectively eliminating any
steric hindrance that may have prevented maleate formation in the final step of the
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original synthetic approach. The phenol will first be reacted with maleic anhydride to
create the maleate intermediate 9 that can be subsequently reacted with NBS in the
presence of AIBN to yield the desired maleate binding group 10 with the reactive
benzylic bromide for functionalization of the poly-DMAEMA (Scheme 13).

Scheme 13. Proposed synthesis of the maleate binding group from p-cresol.
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SUMMARY AND OUTLOOK
Significant progress was achieved towards the synthesis of a binding group for the
attachment of the functionalized polyacrylate to the hemoglobin shell. It was found that
an alkyl bromide is not sufficiently reactive with the NMe 2 groups of the polyDMAEMA under mild conditions. The synthetic approach has therefore been modified to
incorporate a benzylic bromide which will allow for the functionalization of the NMe 2
groups of the polymer at lower temperatures. Multiple synthetic approaches were
explored to synthesize a binding group possessing both the maleate and benzyl bromide
functionalities critical to design of the binding group. In the first approach, 2,6-di-tertbutyl-4-methylphenol was successfully brominated to install a benzylic bromide,
however, functionalization with maleic anhydride was unsuccessful, likely due to steric
hindrance of the tert-butyl groups. In the second approach, the phenol was replaced with
an aniline derivative that was contrarily easily functionalized with maleic anhydride,
however, unfortunately unsuccessful in bromination of the benzylic carbon. In the latest
revised approach, it is suggested that the phenol derived binding group be revisited,
replacing the 2,6-di-tert-butyl-4-methylphenol with p-cresol to eliminate the steric
hindrance that prevented maleic acid functionalization in the original approach. This
latest synthetic approach is promising in yielding our desired binding group with both the
maleate and benzylic bromide functionalities. The binding group, TEMPO, and PEG
moieties will be able to be incorporated into the post-polymerization functionalization
process to yield functionalized polyacrylates with controlled functional densities. With
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the functionalized polyacrylates in hand, the attachment of the multi-functional polymer
to the hemoglobin shell can then be studied.
In conclusion, we have refined the synthetic approach to the synthesis a binding group
moiety for the attachment of multi- functional polyacrylates to cell-free Hb. These results
bring us one step closer to the finalization of a new generation of PNPH type molecules
that are both more cost effective and synthetically practicable for widespread
pharmaceutical application.
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EXPERIMENTAL
Materials:
All starting materials were purchased from commercial sources and solvents were used as
they came. Nuclear magnetic resonance (NMR) spectra were obtained using an Agilent
Technologies 400 MHz NMR.

Experimental:
Synthesis of bromoethylmaleate binding group 1:
To a round bottom flask equipped with stir bar was added maleic anhydride (1.05 g, 10.7
mmol) in 35 mL DCM. To the flask, triethylamine (1.63 g, 16.1 mmol) and 2bromoethanol (1.32 g, 10.6 mmol) were added. The reaction was stirred overnight at
room temperature. The reaction mixture was then extracted three times using 0.5 mL HCl
(0.35 M) in 30 mL of DI water. The extracted organic (DCM) layer was dried over
anhydrous sodium sulfate and concentrated under reduced pressure to yield the desired
bromoethylmaleate binding group (0.91 g, 4.1 mmol, 38.4%).

Radical bromination of 2,6-di-tert-butyl-4-methylphenol:
To a round bottom flask equipped with stir bar was added 2,6-di-tert-butyl-4methylphenol (2.00 g, 9.1 mmol) in 30 mL chloroform. To the flask, Nbromosuccinimide (1.68 g, 9.4 mmol) and 2,2′-azobis(2-methylpropionitrile) (0.04 g,
0.24 mmol) were added, and the reaction was refluxed overnight. The chloroform was
removed under reduced pressure and the desired product was precipitated from 30 mL of
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heptane. The precipitate was isolated using vacuum filtration to yield the pure brominated
2,6-di-tert-butyl-methylphenol product (2.72 g, 9.1 mmol, 73.9%).

Addition of maleic anhydride to compound 2 under basic conditions:
To a round bottom flask equipped with stir bar, maleic anhydride (0.92 g, 9.4 mmol) in
30 mL DCM was added. To the flask, triethylamine (0.93 g, 9.2 mmol) and compound 2
(2.77 g, 9.3 mmol) were added, and the reaction was stirred at room temperature
overnight. The DCM was then removed under reduced pressure and the product was
precipitated from 80 mL of t-butyl methyl ether. The precipitate was then isolated via
vacuum filtration to yield a white solid (1.42 g).

Addition of maleic anhydride to phenolate derivative:
To a round bottom flask equipped with stir bar, 2,6-di-tert-butyl-4-methylphenol (2.35 g,
10.7 mmol) was added in 30 mL of methanol. To the flask, sodium methoxide (0.59 g,
10.9 mmol) was added and the reaction was stirred for 5 minutes. The methanol was
removed under reduced pressure to yield 2,6-di-tert-butyl-4-methylphenolate as a green
solid (3.8 g, 17.5 mmol). To the phenolate flask, was added maleic anhydride (1.75 g,
17.9 mmol) in 30 mL of DCM. The reaction was stirred at room temperature overnight.
The reaction mixture was then extracted using 0.5 M NaHCO3 (30 mL), and the organic
(DCM) layer was dried over anhydrous sodium sulfate and concentrated under reduced
pressure to yield a yellow solid (2.32 g).
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Addition of maleic anhydride to 4-methylaniline:
To a round bottom flask equipped with stir bar, maleic anhydride (1.37 g, 14.0 mmol) in
75 mL DCM was added. To the flask, 4-methylaniline (1.47 g, 13.7 mmol) was added
and the reaction was stirred at room temperature overnight. The product precipitated and
was subsequently isolated via vacuum filtration. The desired maleimide product was a
yellow solid (3.01 g, 14.7 mmol, 106%).

Radical bromination of compound 6:
To a pressure vessel equipped with stir bar, compound 6 (0.54 g, 2.6 mmol) in 40 mL of
chloroform was added. To the flask, N-bromosuccinimide (0.92 g, 5.2 mmol) and 2,2′azobis(2-methylpropionitrile) (0.03 g, 0.18 mmol) were added, and the reaction was
stirred overnight at 110 °C. The product precipitated and was subsequently isolated via
vacuum filtration to yield a yellow solid (0.74 g).
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